Copyright 2024 All rights reserved.

Pipelines

Stem Medicare is developing EV-based new drugs for various diseases

as well as regenerative medicines based on the world's only non-immunogenic,

immune-tolerized extracellular vesicle technology.

Pipelines

Infectious Diseases

Immune-tolerized EV therapeutics for prevention and treatment of all infectious diseases (MBTC-IgP-EVs)

MBTC-IgP-EVs
contain IgP, IgM, complement proteins, and anti-viral proteins

(Primal Immune System)
Primal

Immune

System
MBTC-lgP-EVs
  • IgP / IgM
  • Complement proteins
  • IFN-γ induced

    anti-viral proteins
  • Enhancing innate immunity to fast

    induce adaptive immunity
  • Safe to use by anyone,

    even those with weak immunity
  • Reduced infection and

    fatality rates of the elderly
  • Protection against various mutated and

    latent viruses or pathogens
  • Extension of protection

    period for vaccination
  • Simultaneous activation of antibody and

    cellular adaptive immunities
MBTC-IgP-EVs
IgP (Primal Immunoglobulin)
  • Immune-tolerized extracellular vesicle therapeutics for prevention and treatment of all infectious diseases
  • MOA : Enhancing innate immunity and fast inducing antigen-specific adaptive immunity
  • Capable to be used alone or in combination with vaccine antigen as a VACCINE ADJUVANT

Vaccine Adjuvant :
Substances added to enhance the protective ability of vaccines

Unmet needs of
current vaccine adjuvants

Next-Generation Vaccine Adjuvant Platform Technology

Both activations of antibody and cellular adaptive immunities without side effects